Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations study observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By influ... https://danielf924dxr0.wiki-cms.com/user